Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maria Luisa Barzelloni"'
Autor:
Anna Mogavero, Francesca Vecchione, Pietro Carnicelli, Rosanna Izzo, Maria Luisa Barzelloni, Valeria Crivaro, Antonella Spezia, Maria De Filippo, Pietro Deluca, Maria Citera
Publikováno v:
Neuropathological Diseases. 2:15-20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f19376ee392ca64770b64c9356f5c49b
https://doi.org/10.1615/neuropatholdiseases.v2.i1.20
https://doi.org/10.1615/neuropatholdiseases.v2.i1.20
Autor:
Enrico Barbato, Vincenzo Montesarchio, Agata Pisano, Michelino De Laurentiis, Fortunato Ciardiello, Geppino Genua, Roberta Caputo, Ferdinando Riccardi, Adriano Gravina, Maria Luisa Barzelloni, Giuseppe Grimaldi, Carmela Mocerino, Raffaele Nettuno, A. Diana, Alessio Fabozzi, Pasquale Incoronato, Luigi Leopaldi, Giovanni Iodice, Guido Giordano, Michele Orditura, E. Procaccini, Roberto Mabilia, Antonio Febbraro, Eva Lieto
Publikováno v:
ESMO Open
Background On the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02c599fcccc8d6ec383f496c2151633b
https://doi.org/10.1136/esmoopen-2017-000176
https://doi.org/10.1136/esmoopen-2017-000176
Publikováno v:
Giornale italiano di medicina del lavoro ed ergonomia. 34(2 Suppl)
The Equi-Car 10 is an spontaneous, observational study. The objective was to assess the connection of fatigue perception and depression of caregivers, oncological team and oncological patients in oral chemotherapy to intravenousThe study recruited 60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::527d27c2378b6ab262d960397ce666d1
https://pubmed.ncbi.nlm.nih.gov/23326937
https://pubmed.ncbi.nlm.nih.gov/23326937
Autor:
Cesare, Gridelli, Antonio, Rossi, Paolo, Maione, Ciro, Guerriero, Giuseppe, Airoma, Giuseppe, Colantuoni, Maria Luisa, Barzelloni
Publikováno v:
Anticancer research. 24(3b)
To evaluate the tolerabiliy and activity of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small cell lung cancer (NSCLC).From July 2001 to August 2003, we analysed, retrospectively,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::725e86c9a735f1a2dd5da6a0c26b9f8f
https://pubmed.ncbi.nlm.nih.gov/15274368
https://pubmed.ncbi.nlm.nih.gov/15274368